Announced
Completed
Financials
Sources
Tags
Biotechnology
Majority
Completed
Venture Capital
United States
Friendly
care of cancer patients
Domestic
Acquisition
Single Bidder
Private Equity
Private
Synopsis
Hologic, a medical technology company, completed the acquisition of BioTheranostics, a company that improves the care of cancer patients, offering a suite of proprietary genomics-based molecular diagnostics that allow treatment to be tailored to individual patients, from MVM Partners, a venture capital firm, Evidity Health Care, a company that specializes in medical devices, and HealthQuest Capital, a sector-specialist manager that provides growth capital to transformative companies, for £169m. “Acquiring Biotheranostics leverages our strengths in molecular diagnostics and complements our leadership in breast health, while providing attractive growth and return on invested capital,” Steve MacMillan, Hologic Chairman, President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.